Join Clinical Trials
  • Login
  • Home
  • Clinical Trials by Location
  • Maine


Menu

Choose Which Database to Search - Volunteer Database - Clinical Trial Database Create an Account - VOLUNTEER Accounts - RECRUITER Accounts Account Login - Volunteers Login - Recruiters Login Join a Clinical Trial Clinical Trials by Category Clinical Trials by Location Submit a Clinical Trial Frequently Asked Questions Contact Us Sitemap Blog

Categories

    Healthy Volunteers Adults - 18 - 64 Youths - Birth - 17 Seniors - 65 + Expanded Access Compensated Trials Clinical Trials by Condition Trials by Drug Type Trials for Rare Conditions

Recent Listings

  • Post your clinical trial on JoinClinicalTrials.com

    Ellijay, Georgia 30536
    United States

    Post your clinical trial on JoinClinicalTrials.com

    05-09-2019 01:01PM

| JoinClinicalTrials.com

Maine

Clinical Trials by Location Maine

Auburn

Augusta

Bangor

Bath

Belfast

Biddeford

Brewer

Brunswick

Freeport

Hermon

Kennebunk

Lewiston

Norway

Portland

Rockport

Sanford

Scarborough

South Portland

Togus

Topsham

Waterville

York


  • Validation of a Shared Decision-Making Tool for Multiple Sclerosis
    NCT04122989
    Condition:   Multiple Sclerosis
    Intervention:   Other: MS-SUPPORT
    Sponsors:   Shared Decision Making Resources;   EMD Serono;   Multiple Sclerosis Association of America;   Multiple Sclerosis Alliance of Southern Colorado
    Recruiting
  • Efficacy of CPP-ACP on Bleaching Related Sensitivity
    NCT04112706
    Conditions:   Teeth Sensitivity;   Tooth Discoloration
    Intervention:   Drug: CPP-ACP
    Sponsors:   University of New England;   University of Iowa
    Completed
  • The Impact of Holding on Stress and Bonding in Mother-Infant Pairs During Therapeutic Hypothermia
    NCT03837717
    Conditions:   Hypoxic-Ischemic Encephalopathy;   Neonatal Encephalopathy
    Interventions:   Behavioral: Holding;   Other: Saliva collection;   Behavioral: No Holding
    Sponsor:   Maine Medical Center
    Recruiting
  • Echocardiographic Risk Factors of Stroke in Patients With Atrial Fibrillation
    NCT03824509
    Conditions:   Atrial Fibrillation;   Stroke
    Intervention:   Other: Chart Review
    Sponsor:   Penobscot Bay Medical Center
    Enrolling by invitation
  • Short Interval Resveratrol Trial in Cardiovascular Surgery
    NCT03762096
    Conditions:   Diabetes Mellitus, Type 2;   Coronary Artery Disease
    Interventions:   Dietary Supplement: Trans-resveratrol;   Dietary Supplement: Placebo
    Sponsors:   Maine Medical Center;   American Heart Association
    Recruiting
  • Effects of Mediterranean Diet Intervention in Diabetic Heart Disease
    NCT03757845
    Conditions:   Diabetes Complications;   Cardiovascular Diseases
    Intervention:   Other: Mediterranean Diet
    Sponsor:   Maine Medical Center
    Recruiting
  • Telemedicine to Improve Use of Therapeutic Hypothermia in Rural Settings
    NCT03706417
    Condition:   Neonatal Encephalopathy
    Intervention:   Diagnostic Test: Telemedicine consult
    Sponsor:   Maine Medical Center
    Recruiting
  • Study of Peripherally Inserted Venous Catheters in Cystic Fibrosis Patients
    NCT03674216
    Condition:   Cystic Fibrosis
    Intervention:  
    Sponsors:   Jonathan B. Zuckerman;   Maine Medical Center;   Cystic Fibrosis Foundation
    Recruiting
  • Neuroinflammatory Response and Headache Control in Patients After Subarachnoid Hemorrhage
    NCT03604276
    Conditions:   Subarachnoid Hemorrhage, Aneurysmal;   Headache;   Subarachnoid Hemorrhage
    Intervention:  
    Sponsor:   Maine Medical Center
    Recruiting
  • Micronutrients as Adjunctive Treatment for Bipolar Disorder
    NCT03541031
    Condition:   Bipolar Disorder
    Interventions:   Dietary Supplement: Micronutrient & Fish oil;   Dietary Supplement: Olive oil & Safflower oil
    Sponsor:   Eastern Maine Medical Center
    Recruiting
  • The Pain App Study: A Novel Shared Decision Making Tool for People With Chronic Pain
    NCT03425266
    Condition:   Chronic Pain
    Intervention:   Other: Interactive decision support tool
    Sponsors:   Shared Decision Making Resources;   University of New England;   Pfizer
    Enrolling by invitation
  • Twice Daily Versus Twice Weekly Soak-and-Seal Baths in Pediatric Atopic Dermatitis
    NCT03397979
    Condition:   Atopic Dermatitis
    Intervention:   Behavioral: Infrequent versus Frequent Soaking Baths
    Sponsor:   Maine Medical Center
    Completed
  • OMT to Improve Feeding After Hypothermia
    NCT03380013
    Conditions:   Neonatal Encephalopathy;   Feeding; Difficult, Newborn
    Intervention:   Procedure: Osteopathic Manipulative Treatment (OMT)
    Sponsor:   Maine Medical Center
    Completed
  • Treatment of HFpEF With Nitrate Supplement
    NCT03289481
    Condition:   Heart Failure With Normal Ejection Fraction
    Interventions:   Dietary Supplement: Active lozenge;   Drug: Placebo
    Sponsors:   Penobscot Bay Medical Center;   HumanN
    Completed
  • Study to Evaluate the Effectiveness of SGB in Preventing Post-op Atrial Fibrillation
    NCT03269383
    Condition:   Atrial Fibrillation
    Interventions:   Drug: Bupivacaine;   Other: Saline
    Sponsor:   Christopher Connors, MD
    Withdrawn
  • Does Deep Neuromuscular Blockade Improve Operating Conditions During Total Hip Replacements?
    NCT03219294
    Condition:   Arthropathy of Hip
    Interventions:   Drug: Vecuronium 0.1 mg/kg;   Drug: Vecuronium 0.2mg/kg
    Sponsors:   Craig Curry;   Maine Medical Center;   Spectrum Medical Group Anesthesiology
    Completed
  • Anticoagulation Therapy in the Very Old
    NCT03103763
    Condition:   Atrial Fibrillation
    Intervention:   Drug: Warfarin
    Sponsor:   Robert W. Stein, MD
    Active, not recruiting
  • Holding, Stress, and Bonding During Therapeutic Hypothermia
    NCT03079284
    Condition:   Hypoxic-Ischemic Encephalopathy
    Intervention:   Other: Holding during cooling
    Sponsor:   Maine Medical Center
    Completed
  • A Study of Tobacco Smoke and Children With Respiratory Illnesses
    NCT03062709
    Conditions:   Bronchiolitis;   Pneumonia;   Reactive Airway Disease;   Asthma;   Tobacco Smoking;   Tobacco Cessation;   Bronchopulmonary Dysplasia
    Interventions:   Behavioral: Breathe Easy Coalition written materials;   Behavioral: Maine Tobacco Helpline;   Diagnostic Test: Urine cotinine testing
    Sponsor:   Maine Medical Center
    Completed
  • Delayed Rewarming for Neuroprotection in Infants Following Cardiopulmonary Bypass Surgery
    NCT03036072
    Condition:   Post-Op Complication
    Interventions:   Other: Strict normothermia;   Device: Delayed Rewarming
    Sponsor:   Maine Medical Center
    Completed
  • A Comparison of Electromyographic Activity & Glenohumeral Motion
    NCT03001908
    Condition:   Orthopedic Disorder
    Interventions:   Other: glenohumeral mobilization-oscillation;   Other: glenohumeral mobilization-sustained
    Sponsor:   University of New England
    Completed
  • Decreasing Rates of Intraurethral Catheterization Postoperatively in Spine Surgery
    NCT02919436
    Condition:   Post-operative Urinary Retention
    Interventions:   Drug: Tamsulosin;   Drug: Placebo
    Sponsor:   Maine Medical Center
    Recruiting
  • Studies of Neuregulin/ERBB Signaling in Human Heart
    NCT02820233
    Conditions:   Heart Disease;   Vascular Disease;   Heart Failure
    Intervention:  
    Sponsors:   Douglas B. Sawyer;   Maine Medical Center
    Recruiting
  • Neuregulin-1, Lipidomics, and Inflammation After Resuscitation From Cardiac Arrest
    NCT02664831
    Conditions:   Cardiac Arrest;   Inflammation;   Obesity
    Intervention:  
    Sponsor:   Maine Medical Center
    Recruiting
  • Clinical Trial Comparing Tranexamic Acid (TXA) With Aquamantys Sealer in Total Knee Arthroplasty (TKA)
    NCT02374398
    Condition:   Blood Loss
    Interventions:   Drug: Tranexamic Acid;   Device: Aquamantys System;   Other: Control
    Sponsor:   Eastern Maine Medical Center
    Completed
  • Comparing Femoral Nerve Catheters to Single Shot Femoral Nerve Blocks for Total Knee Replacement Surgery
    NCT02106481
    Condition:   Knee Osteoarthritis
    Interventions:   Drug: Femoral Nerve Catheters;   Drug: Single Shot Femoral Nerve Blocks
    Sponsor:   Eastern Maine Medical Center
    Completed
  • Safety, Reactogenicity and Immunogenicity of Flublok Quadrivalent (Recombinant Influenza Vaccine,Seasonal Formulation)
    NCT01959945
    Condition:   Influenza
    Interventions:   Biological: Flublok® Quadrivalent Influenza Virus Vaccine;   Biological: Fluarix Quadrivalent® Influenza Virus Vaccine
    Sponsor:   Protein Sciences Corporation
    Completed
  • Effect of Tyrosine Supplementation on Cognitive Performance and Mood During Military Stress
    NCT01913925
    Condition:   Reaction to Severe Stress, Unspecified
    Interventions:   Other: Tyrosine-Containing Food Bar;   Other: Placebo Bar
    Sponsor:   United States Army Research Institute of Environmental Medicine
    Completed
  • Treatment of Neonatal Abstinence Syndrome
    NCT01723722
    Condition:   Neonatal Abstinence Syndrome
    Interventions:   Drug: Methadone;   Drug: Diluted Deodorized Tincture of Opium
    Sponsor:   Eastern Maine Medical Center
    Completed
  • Hydroxycobalamin and Rural Emergency Medical Services Cyanide Exposure Patients: A Cost Analysis
    NCT01656616
    Condition:   Cyanide Poisoning
    Intervention:   Drug: Cyanide antidote administration
    Sponsor:   Maine Medical Center
    Withdrawn
  • Psychosis: Early Detection, Intervention and Prevention
    NCT01597141
    Conditions:   Prodromal Schizophrenia;   Psychotic Disorders;   Severe Bipolar Disorder With Psychotic Features;   Severe Major Depression With Psychotic Features
    Interventions:   Behavioral: Family-aided Assertive Community Treatment;   Behavioral: Enhanced standard treatment
    Sponsors:   Maine Medical Center;   Columbia University;   Harvard University;   University of California, Irvine
    Completed
  • The Effect of the Hemobag® Ultrafiltration System on Blood Conservation and Coagulation After Cardiopulmonary Bypass
    NCT01435304
    Condition:   Blood Coagulation Disorders
    Intervention:   Device: method of returning residual CPB blood ( Hemobag®)
    Sponsors:   Maine Medical Center;   Global Blood Resources, LLC
    Completed
  • X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED) Carrier Outlook Toward Reproduction Survey
    NCT01398813
    Conditions:   Hypohidrotic Ectodermal Dysplasia;   X-Linked Hypohidrotic Ectodermal Dysplasia
    Intervention:  
    Sponsor:   Edimer Pharmaceuticals
    Completed
  • Vasopressin Effects on Human Social Communication
    NCT01327027
    Condition:   Healthy
    Interventions:   Drug: Vasopressin, Arginine, ADH;   Drug: Placebo; Sterile Saline
    Sponsors:   Bowdoin College;   Maine Medical Center;   National Institute of Mental Health (NIMH)
    Completed
  • Testing Spread and Implementation of Novel Methicillin Resistant Staphylococcal Aureus (MRSA)-Reducing Practices
    NCT01255943
    Conditions:   Blood Stream Infections;   MRSA Infections
    Intervention:   Behavioral: healthcare staff processes for infection prevention
    Sponsors:   Maine Medical Center Research Institute;   Agency for Healthcare Research and Quality (AHRQ);   Indiana University School of Medicine
    Completed
  • Prophylaxis to Reduce Postoperative Atrial Fibrillation in Cardiac Surgery
    NCT00953212
    Conditions:   Atrial Fibrillation;   Atrial Flutter
    Interventions:   Drug: beta blockers;   Drug: amiodarone;   Drug: ascorbic acid
    Sponsor:   Maine Medical Center
    Completed
  • Family Exergaming: A Research Study Testing a Videogame Intervention to Increase Physical Activity for Families
    NCT00889122
    Condition:   Obesity
    Intervention:   Behavioral: Exergame (DDR)
    Sponsors:   Maine Medical Center;   Robert Wood Johnson Foundation
    Completed
  • The Influence of Remote Ischemic Preconditioning on Acute Kidney Injury After Cardiac Surgery
    NCT00821522
    Conditions:   Acute Kidney Insufficiency;   Acute Renal Insufficiency;   Acute Kidney Injury;   Ischemic Preconditioning
    Intervention:   Procedure: Remote Ischemic Preconditioning
    Sponsor:   Maine Medical Center Research Institute
    Unknown status
  • Deep Dive Randomized Control Trial
    NCT00793260
    Conditions:   Chronic Disease;   Arthritis;   Uterine Diseases;   Spinal Diseases;   Preventive Health Services
    Interventions:   Behavioral: Enhanced Support;   Behavioral: Usual-Support
    Sponsors:   Health Dialog;   Health Net California;   Highmark Blue Cross Blue Shield
    Completed
  • Reduction of Mortality Prior to and During the First 90 Days of Dialysis Through a Renal Rehabilitation Program
    NCT00792454
    Conditions:   Chronic Kidney Disease;   End Stage Kidney Disease;   Cardiovascular Disease
    Intervention:   Behavioral: exercise training
    Sponsor:   Maine Medical Center
    Completed
  • NOVA22007 0.05% and 0.1% Cyclosporine Versus Vehicle for the Treatment of Dry Eye
    NCT00739349
    Condition:   Dry Eye
    Interventions:   Drug: NOVA22007 ''Cyclosporine'';   Drug: vehicle/placebo
    Sponsor:   Santen SAS
    Completed
  • Study of Osteopathic Manipulation in the Management of Angina
    NCT00708279
    Condition:   Angina Pectoris
    Intervention:   Procedure: Osteopathic manipulation
    Sponsors:   University of New England;   Osteopathic Heritage Foundations
    Completed
  • AV Fistula Salvage in Advanced CKD Using Sodium Bicarbonate Prophylaxis
    NCT00621972
    Condition:   Acute Renal Failure
    Intervention:  
    Sponsor:   Maine Medical Center
    Withdrawn
  • The Efficacy of Tamsulosin in the Treatment of Ureteral Stones in Emergency Department Patients
    NCT00600405
    Conditions:   Nephrolithiasis;   Ureteral Calculi
    Interventions:   Drug: tamsulosin;   Drug: Standard therapy with ibuprofen and oxycodone.
    Sponsors:   Maine Medical Center;   Maine Medical Center Mentored Research Committee
    Completed
  • Study of Cyclosporine in the Treatment of Dry Eye Syndrome (ST-603-007)
    NCT00548301
    Condition:   Dry Eye Syndromes
    Intervention:   Drug: cyclosporine
    Sponsor:   Sirion Therapeutics, Inc.
    Completed
  • Study of Cyclosporine in the Treatment of Dry Eye Syndrome (ST-603-005)
    NCT00502073
    Condition:   Dry Eye Syndromes
    Intervention:   Drug: cyclosporine
    Sponsor:   Sirion Therapeutics, Inc.
    Completed
  • "Generation Fit and Exerlearning With In the Groove"
    NCT00424918
    Condition:   Obesity
    Intervention:   Behavioral: Physical Activity, reduced sedentary behavior
    Sponsor:   Maine Medical Center
    Completed
  • Evaluation of an Investigational Multi-Purpose Disinfecting Solution for the Care of Silicone Hydrogel Soft Contact Lenses
    NCT00382902
    Condition:   Contact Lens Care
    Intervention:   Device: OptiFree Multi-Purpose Disinfecting Solution
    Sponsor:   Alcon Research
    Completed
  • The Triglyceride Lowering Effect of an Omega-3 Fat (DHA) in Addition to Statin Therapy for Patients With CAD or Diabetes
    NCT00360217
    Conditions:   Hypertriglyceridemia (TG>200<500);   Hyperlipidemia;   Coronary Artery Disease;   Coronary Risk Equivalent;   Diabetes
    Intervention:   Drug: docosahexanoic acid (DHA)
    Sponsor:   Maine Center for Lipids and Cardiovascular Health
    Completed
  • Blood Sample Donations to Study the Role of Genes in Pain
    NCT00341367
    Condition:   Pain
    Intervention:  
    Sponsor:   National Institute on Alcohol Abuse and Alcoholism (NIAAA)
    Completed
  • Lamotrigine in Treatment Resistant Depression in Adolescents
    NCT00284791
    Condition:   Adolescent Depression
    Interventions:   Drug: Lamotrigine (drug);   Drug: Fluoxetine (drug);   Drug: sertraline (drug)
    Sponsors:   Maine Medical Center;   GlaxoSmithKline
    Terminated
  • Malignant Obstruction ZILVER Against Routine Therapy (MOZART I)
    NCT00196105
    Conditions:   Biliary Tract Neoplasms;   Pancreatic Neoplasms;   Jaundice, Obstructive
    Interventions:   Device: 6 mm Nitinol Zilver Stent;   Device: 10 mm Nitinol Zilver Stent;   Device: 10 mm Stainless Steel Wallstent
    Sponsor:   Cook Group Incorporated
    Completed
  • The Effect of Thyroid Hormone Levels in Pregnant Women on the Intelligence Quotient (IQ) of Their Children
    NCT00147433
    Conditions:   Child Development Disorders;   Pregnancy;   Subclinical Hypothyroidism
    Intervention:  
    Sponsor:   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
    Unknown status
  • Prenatal Screening For Smith-Lemli-Opitz Syndrome
    NCT00070850
    Conditions:   Smith-Lemli-Opitz Syndrome;   Pregnancy
    Intervention:  
    Sponsor:   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
    Completed
  • Once Weekly Parathyroid Hormone for Osteoporosis
    NCT00065637
    Conditions:   Osteopenia;   Osteoporosis
    Interventions:   Drug: Teriparatide;   Drug: Placebo teriparatide
    Sponsors:   University of California, San Francisco;   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
    Completed
  • Phase 1 Study of HBN-1
    NCT04094857
    Condition:   Cardiac Arrest
    Intervention:   Drug: HBN-1
    Sponsor:   Hibernaid, Inc
    Not yet recruiting
  • Addressing Mental Health Disparities in Refugee Children
    NCT03796065
    Condition:   Family Research
    Intervention:   Behavioral: FSI-R Treatment
    Sponsor:   Boston College
    Recruiting
  • Online Mindfulness-based Tic Reduction (Phase Two)
    NCT03771235
    Conditions:   Tourette Syndrome;   Persistent Tic Disorder
    Interventions:   Behavioral: Mindfulness-based Intervention for Tics;   Behavioral: Tic Information and Coping Strategies
    Sponsors:   Bowdoin College;   Massachusetts General Hospital
    Recruiting
  • Online Mindfulness-based Tic Reduction
    NCT03525626
    Conditions:   Tourette Syndrome;   Tic Disorders
    Intervention:   Behavioral: Online Mindfulness-based Tic Reduction
    Sponsors:   Bowdoin College;   Massachusetts General Hospital
    Completed
  • Safety and Efficacy of BRM421 for Dry Eye Syndrome
    NCT03066219
    Condition:   Dry Eye Syndrome
    Interventions:   Drug: BRM421;   Drug: Placebo
    Sponsor:   BRIM Biotechnology Inc.
    Completed
  • Biomarkers of Iron Homeostasis and Responses to Cystic Fibrosis Pulmonary Exacerbation (CFPE) Treatment
    NCT02188758
    Condition:   Cystic Fibrosis
    Intervention:   Other: Adults - CFPE Treatment
    Sponsors:   Dartmouth-Hitchcock Medical Center;   Maine Medical Center
    Completed
  • Does a Daily Iron Tablet Improve Anemia in Cystic Fibrosis
    NCT01755455
    Conditions:   Cystic Fibrosis;   Anemia, Iron-Deficiency
    Interventions:   Drug: Ferrous sulfate 325mg;   Drug: Placebo
    Sponsor:   Dartmouth-Hitchcock Medical Center
    Completed
  • Balancing Act: Impact on Falls in Older Adults With Vision Impairment
    NCT02074488
    Condition:   Postural Balance
    Interventions:   Other: Balancing Act exercise curriculum;   Other: Informational Brochure
    Sponsors:   University of Maine;   University of New England;   National Institutes of Health (NIH);   National Institute on Aging (NIA)
    Completed
  • Platelet Rich Plasma (PRP) in Total Knee Replacement
    NCT00826098
    Conditions:   Osteoarthritis;   Inflammatory Arthritis
    Intervention:   Biological: Platelet Rich Plasma
    Sponsor:   Exactech
    Completed
  • Safety and Efficacy Study of AzaSite® in Subjects With Blepharitis
    NCT00629941
    Condition:   Blepharitis
    Intervention:   Drug: AzaSite®
    Sponsor:   Merck Sharp & Dohme Corp.
    Completed
  • Osteopathic Otitis Media Research Study
    NCT00520039
    Condition:   Otitis Media With Effusion
    Intervention:   Procedure: osteopathic manipulative medicine (OMM)
    Sponsors:   West Virginia School of Osteopathic Medicine;   University of New England;   American Academy of Osteopathy;   Osteopathic Research Center
    Completed
  • Tocopherols and Alpha Lipoic Acid Treatment Chronic Kidney Disease (TALAT)
    NCT00308971
    Condition:   Chronic Kidney Disease
    Interventions:   Drug: Alpha, gamma, beta, and delta (mixed) tocopherols;   Drug: alpha lipoic acid;   Drug: placebo
    Sponsor:   Vanderbilt University
    Completed
  • Prospective Clinicogenomic Program
    NCT04180176
    Conditions:   Non-Small Cell Lung Cancer (NSCLC);   Small-Cell Lung Cancer (SCLC)
    Intervention:   Other: Blood Draw
    Sponsors:   Genentech, Inc.;   Flatiron Health, Inc.; Foundation Medicine, Inc.
    Not yet recruiting
  • A Community Health Worker Program to Support Rural Older Adults
    NCT03843333
    Conditions:   Frail Elderly;   Cognitive Impairment;   Mobility Limitation;   Depressive Symptoms
    Interventions:   Behavioral: Tai Ji Quan: Moving for Better Balance;   Behavioral: Behavioral Activation;   Other: Resource Navigation;   Other: Enhanced Usual Care
    Sponsors:   University of Vermont;   Central Vermont Medical Center;   Dartmouth College;   Dartmouth-Hitchcock Medical Center;   Maine Medical Center;   MaineGeneral Health;   Maine-Dartmouth Family Medicine Residency;   Dartmouth SYNERGY Clinical and Translational Science Institute;   Northern New England Clinical and Translational Research Network
    Recruiting
  • Multimedia Training for Family Caregivers in Use of Touch and Massage in Supportive Cancer Care
    NCT00632398
    Condition:   Cancer
    Interventions:   Behavioral: Attention control (reading);   Behavioral: Touch, Caring and Cancer DVD program
    Sponsors:   Collinge and Associates, Inc.;   National Cancer Institute (NCI)
    Completed
  • Redesigning Cardiac Surgery to Reduce Neurologic Injury
    NCT00432536
    Conditions:   Cardiovascular Disease;   Surgery
    Intervention:   Other: Quality improvement intervention
    Sponsors:   Dartmouth-Hitchcock Medical Center;   Maine Medical Center;   Catholic Medical Center;   Somanetics Corporation;   LivaNova;   Maquet Cardiovascular;   Northern New England Cardiovascular Disease Study Group;   Luna Innovations;   Agency for Healthcare Research and Quality (AHRQ)
    Completed
  • Efficacy and Safety Study for Ecabet Ophthalmic Solution for Treating Dry Eye Syndrome
    NCT00198536
    Condition:   Dry Eye Syndromes
    Interventions:   Drug: Ecabet 2.83%;   Drug: Ecabet 3.70%;   Drug: Vehicle
    Sponsor:   Bausch & Lomb Incorporated
    Completed
  • Indomethacin Germinal Matrix Hemorrhage/Intraventricular Hemorrhage (GMH/IVH) Prevention Trial
    NCT00033917
    Conditions:   Intraventricular Hemorrhage (IVH);   Bleeding in the Brain;   Prematurity;   Very Low Birth Weight Infants
    Interventions:   Drug: indomethacin;   Drug: placebo
    Sponsor:   Yale University
    Completed
  • Study of TOP1630 for Dry Eye Syndrome
    NCT03833388
    Condition:   Dry Eye Syndrome
    Interventions:   Drug: TOP1630 0.1% Ophthalmic Solution TID OU;   Drug: Placebo to TOP1630 0.1% Ophthalmic Solution TID OU
    Sponsor:   Topivert Pharma Ltd
    Completed
  • Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia
    NCT00477594
    Conditions:   Lipid Metabolism, Inborn Errors;   Hypercholesterolemia, Autosomal Dominant;   Hyperlipidemias;   Metabolic Diseases;   Hyperlipoproteinemia Type II;   Metabolism, Inborn Errors;   Genetic Diseases, Inborn;   Infant, Newborn, Diseases;   Metabolic Disorder;   Congenital Abnormalities;   Hypercholesterolemia;   Hyperlipoproteinemias;   Dyslipidemias;   Lipid Metabolism Disorders
    Intervention:   Drug: mipomersen sodium
    Sponsors:   Kastle Therapeutics, LLC;   Ionis Pharmaceuticals, Inc.
    Completed
  • Treatment Decisions for Multi-vessel CAD
    NCT02611050
    Condition:   Coronary Artery Disease
    Interventions:   Behavioral: The Multi-vessel Coronary Artery Disease Option Grid;   Behavioral: Usual Care
    Sponsor:   Dartmouth-Hitchcock Medical Center
    Terminated
  • Amantadine to Speed Awakening After Cardiac Arrest
    NCT02486211
    Conditions:   Coma;   Heart Arrest;   Anoxia
    Interventions:   Drug: Amantadine;   Drug: Placebo
    Sponsors:   Jon Rittenberger, MD;   American Heart Association
    Completed
  • HOBSCOTCH Phase II
    NCT02394509
    Condition:   Epilepsy
    Intervention:   Behavioral: Home Based Self-management and Cognitive Training Changes lives (HOBSCOTCH)
    Sponsors:   Dartmouth-Hitchcock Medical Center;   Centers for Disease Control and Prevention
    Active, not recruiting
  • A Study Assessing the Safety, Efficacy, and Optimum Dosage of K-161 in Subjects With Moderate to Severe Dry Eye Disease
    NCT04084483
    Condition:   Dry Eye Disease
    Interventions:   Drug: K-161;   Other: Placebo (Vehicle)
    Sponsor:   Kowa Research Institute, Inc.
    Recruiting
  • Cenobamate Open-Label Extension Study for YKP3089C025
    NCT03961568
    Condition:   Primary Generalized Tonic Clonic Seizures in the Setting of Idiopathic Generalized Epilepsy
    Intervention:   Drug: Cenobamate
    Sponsor:   SK Life Science, Inc.
    Enrolling by invitation
  • Pilot Study for Young Women's Intervention
    NCT01647594
    Condition:   Breast Cancer
    Interventions:   Behavioral: YWI;   Behavioral: Physical Activity
    Sponsors:   Dana-Farber Cancer Institute;   American Society of Clinical Oncology
    Completed
  • Prospective Observational Study Evaluating Treatment Decision Impact of Prosigna® in Early Stage Breast Cancer Patients
    NCT02625935
    Condition:   Breast Cancer
    Intervention:  
    Sponsor:   NanoString Technologies, Inc.
    Completed
  • CyclASol for the Treatment of Moderate to Severe Dry-eye Disease (DED)
    NCT02617667
    Condition:   Dry Eye Syndromes
    Interventions:   Drug: Cyclosporine A;   Drug: Placebo
    Sponsor:   Novaliq GmbH
    Completed
  • Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma
    NCT01234766
    Condition:   Lymphoma, Follicular
    Interventions:   Drug: Bendamustine;   Drug: Rituximab;   Radiation: Y-90 ibritumomab
    Sponsors:   Dartmouth-Hitchcock Medical Center;   Cephalon;   Spectrum Pharmaceuticals, Inc
    Active, not recruiting
  • Decision Aid for Renal Therapy
    NCT03522740
    Conditions:   Chronic Kidney Diseases;   Kidney Failure, Chronic
    Intervention:   Other: Decision Aid for Renal Therapy
    Sponsors:   Tufts University;   Patient-Centered Outcomes Research Institute
    Recruiting
  • Pilot Study To Assess CAT-2003 in Patients With Severe Hypertriglyceridemia
    NCT01968720
    Conditions:   Hyperlipidemias;   Hypertriglyceridemia;   Dyslipidemias;   Lipid Metabolism Disorders;   Metabolic Diseases
    Interventions:   Drug: CAT-2003;   Drug: Placebo
    Sponsor:   Catabasis Pharmaceuticals
    Completed
  • Buprenorphine/Naloxone - Facilitated Rehabilitation for Opioid Dependent Adolescents - 1
    NCT00078130
    Condition:   Opioid-Related Disorders
    Intervention:   Drug: Buprenorphine/naloxone
    Sponsor:   University of Pennsylvania
    Completed
  • PaTH Study: Parathyroid Hormone and Alendronate for Osteoporosis
    NCT00005005
    Condition:   Osteoporosis
    Interventions:   Drug: PTH;   Drug: Alendronate
    Sponsors:   Dennis Black;   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
    Completed
  • Early Detection of Ovarian Cancer: GC/FT-ICR Mass Spectrometry and Canine Olfaction
    NCT00757952
    Condition:   Ovarian Cancer
    Interventions:   Other: Fourier transform ion cyclotron resonance mass spectrometry;   Other: chromatography;   Other: diagnostic laboratory biomarker analysis;   Other: questionnaire administration
    Sponsor:   Pine Street Foundation
    Completed
  • Promoting Informed Decisions About Cancer Screening in Older Adults
    NCT03959696
    Condition:   Colorectal Cancer Screening
    Interventions:   Behavioral: Notification;   Behavioral: Training
    Sponsors:   Massachusetts General Hospital;   Maine Medical Center;   Brigham and Women's Hospital;   Newton-Wellesley Hospital;   North Shore Medical Center
    Enrolling by invitation
  • Comparison of Prevena Negative Pressure Incision Management System vs. Standard Dressing After Vascular Surgery
    NCT02389023
    Conditions:   Peripheral Artery Disease;   Critical Limb Ischemia;   Claudication
    Interventions:   Other: standard gauze dressing;   Other: Prevena Incision Management system
    Sponsors:   University of Vermont Medical Center;   KCI USA, Inc.;   Maine Medical Center;   Brigham and Women's Hospital;   Beth Israel Deaconess Medical Center;   Dartmouth-Hitchcock Medical Center
    Recruiting
  • A Safety and Efficacy Study of MIM-D3 Ophthalmic Solution for the Treatment of Dry Eye
    NCT01960010
    Condition:   Dry Eye Syndromes
    Interventions:   Drug: MIM-D3 Ophthalmic Solution;   Drug: Vehicle
    Sponsor:   Mimetogen Pharmaceuticals USA, Inc.
    Completed
  • Targeting Inflammation Using Salsalate in CardioVascular Disease
    NCT00624923
    Conditions:   Coronary Artery Disease;   Overweight
    Interventions:   Drug: Salsalate;   Drug: Placebo
    Sponsors:   Joslin Diabetes Center;   Beth Israel Deaconess Medical Center;   Tufts Medical Center;   National Heart, Lung, and Blood Institute (NHLBI)
    Completed
  • Dose-escalating Safety Study in Subjects on Stable Statin Therapy
    NCT00231569
    Condition:   Hypercholesterolemia
    Intervention:   Drug: ISIS 301012 or Placebo
    Sponsors:   Kastle Therapeutics, LLC;   Ionis Pharmaceuticals, Inc.
    Completed
  • Safety and Efficacy Study of EGP-437 (Dexamethasone Phosphate Formulated for Ocular Iontophoresis) to Treat Dry Eye
    NCT01129856
    Condition:   Dry Eye
    Interventions:   Drug: Dexamethasone phosphate ophthalmic solution;   Drug: Sodium citrate buffer solution
    Sponsor:   Eyegate Pharmaceuticals, Inc.
    Completed
  • Trial of ARI-3037MO to Reduce Triglyceride Levels in Adults With Severe (≥500 mg/dl) Hypertriglyceridemia
    NCT02250105
    Condition:   Hypertriglyceridemia
    Interventions:   Drug: ARI-3037MO;   Drug: Placebo
    Sponsors:   Arisaph Pharmaceuticals Inc;   Baim Institute for Clinical Research
    Completed
  • A Study Evaluating the Efficacy of SAR 1118 (0.1%, 1.0%, 5.0%) Ophthalmic Solution in Subjects With Dry Eye Conducted in a Controlled Adverse Environment (CAE)
    NCT00926185
    Condition:   Dry Eye
    Interventions:   Drug: Lifitegrast;   Drug: Placebo
    Sponsor:   Shire
    Completed
  • RCT of the Restorative Practices Intervention
    NCT02155296
    Conditions:   Intervention Schools (Schools Receiving RPI);   Control Schools (Schools Not Receiving RPI)
    Intervention:   Behavioral: Restorative Practices Intervention
    Sponsors:   RAND;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
    Completed
  • Video Support Program For Families With a Parent Newly Diagnosed With Cancer
    NCT00020553
    Condition:   Psychosocial Effects of Cancer and Its Treatment
    Intervention:   Procedure: psychosocial assessment and care
    Sponsors:   Inflexxion, Inc.;   National Cancer Institute (NCI)
    Unknown status
  • Long-Term Outcomes for Lumbar Spinal Stenosis Patients Treated With X STOP®
    NCT00534092
    Condition:   Lumbar Spinal Stenosis
    Intervention:   Device: X STOP® Interspinous Process Decompression System
    Sponsor:   Medtronic Spine LLC
    Completed
  • Evaluation of Efficacy of Ophthalmic Solution in Induced Acute Allergic Conjunctivitis
    NCT00241319
    Condition:   Allergic Conjunctivitis
    Intervention:   Drug: R89674 (generic name not yet established)
    Sponsor:   Vistakon Pharmaceuticals
    Completed
  • Therapy for Pediatric Hodgkin Lymphoma
    NCT00145600
    Condition:   Hodgkin Lymphoma
    Interventions:   Drug: 12 Week Stanford V Chemotherapy;   Drug: 4 cycles of VAMP chemotherapy;   Drug: 2 alternating cycles of VAMP/COP chemotherapy;   Drug: 3 alternating cycles of VAMP/COP chemotherapy
    Sponsor:   St. Jude Children's Research Hospital
    Active, not recruiting
  • An Evaluation of Innerview™, a Web-based Tool to Support the Integration of Mental Health in the Primary Care Setting
    NCT02025647
    Condition:   Mental Health
    Intervention:  
    Sponsor:   Pearson/Clinical Assessment
    Completed
  • Safety and Efficacy Study of Rebamipide 2% Ophthalmic Suspension in Patients With Dry Eye
    NCT01027013
    Conditions:   Dry Eye Syndromes;   Keratoconjunctivitis Sicca
    Interventions:   Drug: rebamipide 2% ophthalmic suspension;   Drug: placebo eye drops
    Sponsors:   Acucela Inc.;   Otsuka Pharmaceutical Co., Ltd.
    Completed
  • Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
    NCT03907488
    Conditions:   Ann Arbor Stage III Hodgkin Lymphoma;   Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma;   Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma;   Ann Arbor Stage III Nodular Sclerosis Classic Hodgkin Lymphoma;   Ann Arbor Stage IIIA Hodgkin Lymphoma;   Ann Arbor Stage IIIB Hodgkin Lymphoma;   Ann Arbor Stage IV Hodgkin Lymphoma;   Ann Arbor Stage IV Lymphocyte-Depleted Classic Hodgkin Lymphoma;   Ann Arbor Stage IV Mixed Cellularity Classic Hodgkin Lymphoma;   Ann Arbor Stage IV Nodular Sclerosis Classic Hodgkin Lymphoma;   Ann Arbor Stage IVA Hodgkin Lymphoma;   Ann Arbor Stage IVB Hodgkin Lymphoma;   Classic Hodgkin Lymphoma;   Lymphocyte-Rich Classic Hodgkin Lymphoma
    Interventions:   Drug: Brentuximab Vedotin;   Drug: Dacarbazine;   Drug: Doxorubicin;   Drug: Doxorubicin Hydrochloride;   Biological: Filgrastim;   Biological: Nivolumab;   Biological: Pegfilgrastim;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Radiation Therapy;   Drug: Vinblastine;   Drug: Vinblastine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer
    NCT03952585
    Conditions:   Basaloid Squamous Cell Carcinoma;   Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Oropharyngeal Squamous Cell Carcinoma;   Papillary Squamous Cell Carcinoma;   Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
    Interventions:   Drug: Cisplatin;   Radiation: Image Guided Radiation Therapy;   Radiation: Intensity-Modulated Radiation Therapy;   Biological: Nivolumab;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   National Cancer Institute (NCI);   NRG Oncology
    Recruiting
  • Chemoradiation With or Without Atezolizumab in Treating Patients With Limited Stage Small Cell Lung Cancer
    NCT03811002
    Conditions:   Limited Stage Lung Small Cell Carcinoma;   Stage I Lung Cancer AJCC v8;   Stage IA1 Lung Cancer AJCC v8;   Stage IA2 Lung Cancer AJCC v8;   Stage IA3 Lung Cancer AJCC v8;   Stage IB Lung Cancer AJCC v8;   Stage II Lung Cancer AJCC v8;   Stage IIA Lung Cancer AJCC v8;   Stage IIB Lung Cancer AJCC v8;   Stage III Lung Cancer AJCC v8;   Stage IIIA Lung Cancer AJCC v8;   Stage IIIB Lung Cancer AJCC v8;   Stage IIIC Lung Cancer AJCC v8
    Interventions:   Radiation: 3-Dimensional Conformal Radiation Therapy;   Drug: Atezolizumab;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Etoposide;   Radiation: Intensity-Modulated Radiation Therapy;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   National Cancer Institute (NCI);   NRG Oncology
    Recruiting
  • Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer
    NCT03775265
    Conditions:   Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall;   Bladder Urothelial Carcinoma;   Stage II Bladder Cancer AJCC v8;   Stage III Bladder Cancer AJCC v8;   Stage IIIA Bladder Cancer AJCC v8
    Interventions:   Drug: Atezolizumab;   Drug: Cisplatin;   Drug: Fluorouracil;   Drug: Gemcitabine;   Drug: Mitomycin;   Other: Quality-of-Life Assessment;   Radiation: Radiation Therapy;   Other: Survey Administration
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers
    NCT03768414
    Conditions:   Stage III Distal Bile Duct Cancer AJCC v8;   Stage III Gallbladder Cancer AJCC v8;   Stage III Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IIIA Distal Bile Duct Cancer AJCC v8;   Stage IIIA Gallbladder Cancer AJCC v8;   Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IIIB Distal Bile Duct Cancer AJCC v8;   Stage IIIB Gallbladder Cancer AJCC v8;   Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IV Distal Bile Duct Cancer AJCC v8;   Stage IV Gallbladder Cancer AJCC v8;   Stage IV Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IVA Gallbladder Cancer AJCC v8;   Stage IVB Gallbladder Cancer AJCC v8;   Unresectable Extrahepatic Bile Duct Carcinoma;   Unresectable Gallbladder Carcinoma;   Unresectable Intrahepatic Cholangiocarcinoma
    Interventions:   Drug: Cisplatin;   Drug: Gemcitabine Hydrochloride;   Drug: Nab-paclitaxel
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
    NCT03851445
    Condition:   Previously Treated Non-Small Cell Lung Cancer
    Intervention:   Drug: Screening Platform
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
    NCT03845296
    Conditions:   Deleterious BRCA1 Gene Mutation;   Deleterious BRCA2 Gene Mutation;   Loss of Heterozygosity;   Lung Non-Small Cell Squamous Carcinoma;   Recurrent Large Cell Lung Carcinoma;   Recurrent Lung Adenocarcinoma;   Recurrent Lung Non-Small Cell Carcinoma;   Recurrent Non-Squamous Non-Small Cell Lung Carcinoma;   Stage IV Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8
    Intervention:   Drug: Rucaparib
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • BIOMARKER TRIAL of APALUTAMIDE and RADIATION for RECURRENT PROSTATE CANCER
    NCT03371719
    Conditions:   PSA Progression;   Stage III Prostate Adenocarcinoma;   Stage IV Prostate Adenocarcinoma
    Interventions:   Drug: Apalutamide;   Radiation: External Beam Radiation Therapy;   Other: Placebo
    Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
    Recruiting
  • S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
    NCT03499808
    Conditions:   Amorphous, Eosinophilic, and Acellular Deposit;   Constipation;   Diarrhea;   Early Satiety;   Gastrointestinal Hemorrhage;   Hepatomegaly;   Lymphadenopathy;   Macroglossia;   Nausea;   Primary Systemic Amyloidosis;   Purpura;   Recurrent Primary Amyloidosis;   Refractory Primary Amyloidosis
    Interventions:   Biological: Isatuximab;   Other: Laboratory Biomarker Analysis
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer
    NCT03377556
    Conditions:   ATM Gene Mutation;   ATR Gene Mutation;   BARD1 Gene Mutation;   BRCA1 Gene Mutation;   BRCA2 Gene Mutation;   BRIP1 Gene Mutation;   CHEK1 Gene Mutation;   CHEK2 Gene Mutation;   FANCA Gene Mutation;   FANCC Gene Mutation;   FANCD2 Gene Mutation;   FANCF Gene Mutation;   FANCM Gene Mutation;   NBN Gene Mutation;   PALB2 Gene Mutation;   RAD51 Gene Mutation;   RAD51B Gene Mutation;   RAD54L Gene Mutation;   Recurrent Squamous Cell Lung Carcinoma;   RPA1 Gene Mutation;   Stage IV Squamous Cell Lung Carcinoma AJCC v7
    Interventions:   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Talazoparib
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Active, not recruiting
  • Pembrolizumab in Treating Patients With Locally Advanced Bladder Cancer
    NCT03244384
    Conditions:   Stage II Bladder Urothelial Carcinoma AJCC v6 and v7;   Stage III Bladder Urothelial Carcinoma AJCC v6 and v7
    Interventions:   Other: Clinical Observation;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung Cancer
    NCT03382561
    Conditions:   Extensive Stage Lung Small Cell Carcinoma;   Recurrent Lung Small Cell Carcinoma
    Interventions:   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Etoposide;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy
    NCT03055013
    Conditions:   Metastatic Malignant Neoplasm in Lymph Node;   Metastatic Malignant Neoplasm in the Adrenal Gland;   Metastatic Malignant Neoplasm in the Lung;   Metastatic Malignant Neoplasm in the Pancreas;   Metastatic Malignant Neoplasm in the Skin;   Metastatic Malignant Neoplasm in the Soft Tissues;   Metastatic Renal Cell Carcinoma;   Sarcomatoid Renal Cell Carcinoma;   Stage II Renal Cell Cancer AJCC v7;   Stage III Renal Cell Cancer AJCC v7;   Unclassified Renal Cell Carcinoma
    Interventions:   Procedure: Conventional Surgery;   Biological: Nivolumab;   Other: Patient Observation;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   National Cancer Institute (NCI);   Canadian Cancer Trials Group
    Recruiting
  • Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer
    NCT02954874
    Conditions:   Invasive Breast Carcinoma;   Stage 0 Breast Cancer AJCC v6 and v7;   Stage I Breast Cancer AJCC v7;   Stage IA Breast Cancer AJCC v7;   Stage IB Breast Cancer AJCC v7;   Stage II Breast Cancer AJCC v6 and v7;   Stage IIA Breast Cancer AJCC v6 and v7;   Stage IIB Breast Cancer AJCC v6 and v7;   Stage III Breast Cancer AJCC v7;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIB Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7;   Triple-Negative Breast Carcinoma
    Interventions:   Other: Laboratory Biomarker Analysis;   Other: Patient Observation;   Biological: Pembrolizumab;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Radiation Therapy
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy
    NCT02927249
    Condition:   Node Positive HER2 Negative Breast Cancer
    Interventions:   Other: Placebo;   Drug: Aspirin
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   United States Department of Defense;   Bayer;   Canadian Cancer Trials Group
    Recruiting
  • Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
    NCT03092674
    Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndrome;   Myelodysplastic Syndrome With Excess Blasts-2
    Interventions:   Drug: Azacitidine;   Drug: Cytarabine;   Drug: Decitabine;   Other: Laboratory Biomarker Analysis;   Drug: Midostaurin;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Suspended
  • Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
    NCT02912559
    Conditions:   Colon Adenocarcinoma;   DNA Repair Disorder;   Lynch Syndrome;   Stage III Colon Cancer AJCC v7;   Stage IIIA Colon Cancer AJCC v7;   Stage IIIB Colon Cancer AJCC v7;   Stage IIIC Colon Cancer AJCC v7
    Interventions:   Drug: Atezolizumab;   Drug: Fluorouracil;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin;   Other: Quality-of-Life Assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Breast Cancer WEight Loss Study (BWEL Study)
    NCT02750826
    Condition:   Breast Carcinoma
    Interventions:   Other: Health Education Program;   Other: Weight Loss Intervention
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Division of Cancer Control;   NIH Biomarker, Imaging and Quality of Life Studies Funding Program (BIQSFP);   Canadian Cancer Trials Group
    Recruiting
  • Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
    NCT02785952
    Conditions:   Recurrent Squamous Cell Lung Carcinoma;   Stage IV Squamous Cell Lung Carcinoma AJCC v7
    Interventions:   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Active, not recruiting
  • Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)
    NCT02595944
    Conditions:   Stage IB Lung Non-Small Cell Carcinoma AJCC v7;   Stage II Lung Non-Small Cell Cancer AJCC v7;   Stage IIA Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7
    Intervention:   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
    NCT02997228
    Conditions:   Colorectal Adenocarcinoma;   Stage IV Colorectal Cancer AJCC v7;   Stage IVA Colorectal Cancer AJCC v7;   Stage IVB Colorectal Cancer AJCC v7
    Interventions:   Drug: Atezolizumab;   Biological: Bevacizumab;   Drug: Fluorouracil;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   National Cancer Institute (NCI);   NRG Oncology
    Recruiting
  • Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
    NCT02488967
    Conditions:   Breast Adenocarcinoma;   Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor Negative;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIC Breast Cancer;   Triple-Negative Breast Carcinoma
    Interventions:   Drug: Carboplatin;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel
    Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
    Recruiting
  • Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
    NCT02465060
    Conditions:   Advanced Malignant Solid Neoplasm;   Bladder Carcinoma;   Breast Carcinoma;   Cervical Carcinoma;   Colon Carcinoma;   Colorectal Carcinoma;   Endometrial Carcinoma;   Esophageal Carcinoma;   Gastric Carcinoma;   Glioma;   Head and Neck Carcinoma;   Kidney Carcinoma;   Liver and Intrahepatic Bile Duct Carcinoma;   Lung Carcinoma;   Lymphoma;   Malignant Uterine Neoplasm;   Melanoma;   Ovarian Carcinoma;   Pancreatic Carcinoma;   Plasma Cell Myeloma;   Prostate Carcinoma;   Rectal Carcinoma;   Recurrent Bladder Carcinoma;   Recurrent Breast Carcinoma;   Recurrent Cervical Carcinoma;   Recurrent Colon Carcinoma;   Recurrent Colorectal Carcinoma;   Recurrent Esophageal Carcinoma;   Recurrent Gastric Carcinoma;   Recurrent Glioma;   Recurrent Head and Neck Carcinoma;   Recurrent Liver Carcinoma;   Recurrent Lung Carcinoma;   Recurrent Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Melanoma;   Recurrent Ovarian Carcinoma;   Recurrent Pancreatic Carcinoma;   Recurrent Plasma Cell Myeloma;   Recurrent Prostate Carcinoma;   Recurrent Rectal Carcinoma;   Recurrent Skin Carcinoma;   Recurrent Thyroid Gland Carcinoma;   Recurrent Uterine Corpus Carcinoma;   Refractory Lymphoma;   Refractory Malignant Solid Neoplasm;   Refractory Plasma Cell Myeloma;   Skin Carcinoma;   Thyroid Gland Carcinoma;   Uterine Corpus Cancer
    Interventions:   Drug: Adavosertib;   Drug: Afatinib;   Drug: Afatinib Dimaleate;   Drug: Binimetinib;   Drug: Capivasertib;   Drug: Copanlisib;   Drug: Copanlisib Hydrochloride;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Dabrafenib;   Drug: Dabrafenib Mesylate;   Drug: Dasatinib;   Drug: Defactinib;   Drug: Defactinib Hydrochloride;   Drug: Erdafitinib;   Drug: FGFR Inhibitor AZD4547;   Drug: Ipatasertib;   Other: Laboratory Biomarker Analysis;   Drug: Larotrectinib;   Drug: Larotrectinib Sulfate;   Biological: Nivolumab;   Drug: Osimertinib;   Drug: Palbociclib;   Biological: Pertuzumab;   Drug: PI3K-beta Inhibitor GSK2636771;   Drug: Sapanisertib;   Drug: Sunitinib Malate;   Drug: Taselisib;   Drug: Trametinib;   Biological: Trastuzumab;   Biological: Trastuzumab Emtansine;   Drug: Ulixertinib;   Drug: Vismodegib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
    NCT03488693
    Condition:   Breast Cancer
    Interventions:   Radiation: Radiation;   Other: No Radiation
    Sponsors:   Canadian Cancer Trials Group;   Alliance for Clinical Trials in Oncology;   Eastern Cooperative Oncology Group;   NRG Oncology;   Southwest Oncology Group
    Recruiting
  • Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer
    NCT03373760
    Conditions:   Recurrent Squamous Cell Lung Carcinoma;   Stage IV Squamous Cell Lung Carcinoma AJCC v7
    Interventions:   Biological: Durvalumab;   Other: Laboratory Biomarker Analysis;   Biological: Tremelimumab
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
    NCT02201992
    Conditions:   ALK Gene Rearrangement;   ALK Gene Translocation;   ALK Positive;   Stage IB Non-Small Cell Lung Carcinoma AJCC v7;   Stage II Non-Small Cell Lung Cancer AJCC v7;   Stage IIA Non-Small Cell Lung Carcinoma AJCC v7;   Stage IIB Non-Small Cell Lung Carcinoma AJCC v7;   Stage IIIA Non-Small Cell Lung Cancer AJCC v7
    Interventions:   Other: Clinical Observation;   Drug: Crizotinib;   Other: Laboratory Biomarker Analysis
    Sponsors:   ECOG-ACRIN Cancer Research Group;   National Cancer Institute (NCI)
    Recruiting
  • Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
    NCT02194738
    Conditions:   Lung Adenocarcinoma;   Lung Large Cell Carcinoma;   Resectable Lung Non-Small Cell Carcinoma;   Stage IB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IB Lung Squamous Cell Carcinoma AJCC v7;   Stage II Lung Non-Small Cell Cancer AJCC v7;   Stage II Lung Squamous Cell Carcinoma AJCC v7;   Stage IIA Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIA Lung Squamous Cell Carcinoma AJCC v7;   Stage IIB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIB Lung Squamous Cell Carcinoma AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7;   Stage IIIA Lung Squamous Cell Carcinoma AJCC v7
    Interventions:   Other: Clinical Observation;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Erlotinib;   Drug: Erlotinib Hydrochloride;   Biological: Nivolumab;   Other: Placebo Administration
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
    NCT02193282
    Conditions:   EGFR Exon 19 Deletion Mutation;   EGFR NP_005219.2:p.L858R;   Stage IB Lung Non-Small Cell Carcinoma AJCC v7;   Stage II Lung Non-Small Cell Cancer AJCC v7;   Stage IIA Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7
    Interventions:   Other: Clinical Observation;   Drug: Erlotinib;   Drug: Erlotinib Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Placebo Administration
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery
    NCT02196181
    Conditions:   BRAF V600E Mutation Present;   BRAF V600K Mutation Present;   Stage III Cutaneous Melanoma AJCC v7;   Stage IIIA Cutaneous Melanoma AJCC v7;   Stage IIIB Cutaneous Melanoma AJCC v7;   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7;   Unresectable Melanoma
    Interventions:   Drug: Dabrafenib;   Drug: Dabrafenib Mesylate;   Drug: Trametinib;   Drug: Trametinib Dimethyl Sulfoxide
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer
    NCT02154490
    Conditions:   Recurrent Squamous Cell Lung Carcinoma;   Stage IV Squamous Cell Lung Carcinoma AJCC v7
    Interventions:   Drug: Docetaxel;   Biological: Durvalumab;   Drug: Erlotinib Hydrochloride;   Drug: FGFR Inhibitor AZD4547;   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Drug: Palbociclib;   Other: Pharmacological Study;   Biological: Rilotumumab;   Drug: Talazoparib;   Drug: Taselisib;   Biological: Tremelimumab
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Active, not recruiting
  • Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
    NCT02032823
    Condition:   Breast Cancer
    Interventions:   Drug: Olaparib;   Drug: Placebo
    Sponsors:   AstraZeneca;   Breast International Group;   Frontier Science & Technology Research Foundation, Inc.;   NRG Oncology;   Myriad Genetic Laboratories, Inc.;   Br.E.A.S.T. -Data Center & Operational Office Institut Jules Bordet;   Merck Sharp & Dohme Corp.
    Active, not recruiting
  • Standard of Care Therapy With or Without Stereotactic Radiosurgery and/or Surgery in Treating Patients With Limited Metastatic Breast Cancer
    NCT02364557
    Conditions:   Dyspnea;   Fatigue;   Nausea and Vomiting;   Pain;   Stage IV Breast Cancer
    Interventions:   Radiation: Stereotactic Radiosurgery;   Procedure: Therapeutic Conventional Surgery;   Other: Laboratory Biomarker Analysis
    Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
    Recruiting
  • Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery
    NCT03033576
    Conditions:   Advanced Melanoma;   Melanoma of Unknown Primary;   Mucosal Melanoma;   Refractory Melanoma;   Stage III Cutaneous Melanoma AJCC v7;   Stage IIIA Cutaneous Melanoma AJCC v7;   Stage IIIB Cutaneous Melanoma AJCC v7;   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7;   Unresectable Cutaneous Melanoma;   Unresectable Melanoma
    Interventions:   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer
    NCT02965378
    Conditions:   FGFR1 Gene Amplification;   FGFR1 Gene Mutation;   FGFR2 Gene Amplification;   FGFR2 Gene Mutation;   FGFR3 Gene Amplification;   FGFR3 Gene Mutation;   Recurrent Squamous Cell Lung Carcinoma;   Stage IV Squamous Cell Lung Carcinoma AJCC v7
    Interventions:   Drug: Docetaxel;   Drug: FGFR Inhibitor AZD4547;   Other: Laboratory Biomarker Analysis
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Active, not recruiting
  • Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
    NCT02926638
    Conditions:   MET Positive;   Recurrent Squamous Cell Lung Carcinoma;   Stage IV Squamous Cell Lung Carcinoma AJCC v7
    Interventions:   Drug: Erlotinib Hydrochloride;   Other: Laboratory Biomarker Analysis;   Biological: Rilotumumab
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Active, not recruiting
  • Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer
    NCT02785939
    Conditions:   CCND1 Gene Amplification;   CCND2 Gene Amplification;   CCND3 Gene Amplification;   CDK4 Gene Amplification;   Recurrent Squamous Cell Lung Carcinoma;   Stage IV Squamous Cell Lung Carcinoma AJCC v7
    Interventions:   Drug: Docetaxel;   Other: Laboratory Biomarker Analysis;   Drug: Palbociclib
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Active, not recruiting
  • Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
    NCT02785913
    Conditions:   Recurrent Squamous Cell Lung Carcinoma;   Stage IV Squamous Cell Lung Carcinoma
    Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Taselisib
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Active, not recruiting
  • Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
    NCT02766335
    Conditions:   Recurrent Squamous Cell Lung Carcinoma;   Stage IV Squamous Cell Lung Carcinoma AJCC v7
    Interventions:   Drug: Docetaxel;   Biological: Durvalumab;   Other: Laboratory Biomarker Analysis
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Active, not recruiting
  • S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer
    NCT01674140
    Condition:   Breast Cancer
    Interventions:   Drug: anastrozole;   Drug: everolimus;   Drug: exemestane;   Drug: goserelin acetate;   Drug: letrozole;   Drug: leuprolide acetate;   Drug: tamoxifen citrate;   Other: placebo
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Active, not recruiting
  • Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
    NCT01863550
    Condition:   Plasma Cell Myeloma
    Interventions:   Drug: Bortezomib;   Drug: Carfilzomib;   Drug: Dexamethasone;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide;   Other: Quality-of-Life Assessment
    Sponsors:   ECOG-ACRIN Cancer Research Group;   National Cancer Institute (NCI)
    Active, not recruiting
  • Cardiovascular Inflammation Reduction Trial
    NCT01594333
    Condition:   Cardiovascular Disease
    Interventions:   Drug: Methotrexate;   Drug: Placebo
    Sponsors:   Brigham and Women's Hospital;   National Heart, Lung, and Blood Institute (NHLBI)
    Completed
  • Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic
    NCT02115282
    Conditions:   Breast Adenocarcinoma;   HER2/Neu Negative;   Locally Advanced Breast Carcinoma;   Metastatic Breast Carcinoma;   Recurrent Breast Carcinoma;   Stage III Breast Cancer AJCC v7;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIB Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7;   Stage IV Breast Cancer AJCC v6 and v7
    Interventions:   Drug: Entinostat;   Drug: Exemestane;   Drug: Goserelin;   Drug: Goserelin Acetate;   Other: Placebo Administration;   Other: Quality-of-Life Assessment
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors
    NCT02019264
    Conditions:   Cardiovascular Disease;   High Cardiovascular Risk;   Obesity;   Overweight;   Type 2 Diabetes
    Interventions:   Drug: Lorcaserin hydrochloride;   Drug: Placebo
    Sponsors:   Eisai Inc.;   Thrombolysis In Myocardial Infarction (TIMI) Academic Research Organization
    Completed
  • Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
    NCT01275677
    Conditions:   Estrogen Receptor Negative;   Estrogen Receptor Positive;   HER2/Neu Positive;   Progesterone Receptor Negative;   Progesterone Receptor Positive;   Recurrent Breast Carcinoma;   Stage IA Breast Cancer AJCC v7;   Stage IB Breast Cancer AJCC v7;   Stage IIA Breast Cancer AJCC v6 and v7;   Stage IIB Breast Cancer AJCC v6 and v7;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7
    Interventions:   Drug: Cyclophosphamide;   Drug: Docetaxel;   Drug: Doxorubicin;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Other: Quality-of-Life Assessment;   Biological: Trastuzumab
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy
    NCT01901094
    Conditions:   Stage II Breast Cancer;   Stage IIIA Breast Cancer
    Interventions:   Procedure: Axillary Lymph Node Dissection (ALND);   Radiation: Nodal Radiation Therapy;   Radiation: Axillary Radiation Therapy
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Canadian Cancer Trials Group
    Suspended
  • Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia
    NCT01886872
    Conditions:   CD19 Positive;   CD20 Positive;   CD5 Positive;   Stage I Chronic Lymphocytic Leukemia;   Stage II Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage IV Chronic Lymphocytic Leukemia
    Interventions:   Drug: Bendamustine Hydrochloride;   Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Biological: Rituximab
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
    NCT01274338
    Conditions:   Melanoma of Unknown Primary;   Recurrent Melanoma;   Stage IIIB Cutaneous Melanoma AJCC v7;   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7
    Interventions:   Biological: Ipilimumab;   Other: Quality-of-Life Assessment;   Biological: Recombinant Interferon Alfa-2b
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer
    NCT01272037
    Conditions:   Ductal Breast Carcinoma In Situ;   Invasive Breast Carcinoma;   Multicentric Breast Carcinoma;   Multifocal Breast Carcinoma;   Synchronous Bilateral Breast Carcinoma
    Interventions:   Drug: Anastrozole;   Drug: Exemestane;   Other: Laboratory Biomarker Analysis;   Drug: Letrozole;   Other: Quality-of-Life Assessment;   Drug: Systemic Chemotherapy;   Drug: Tamoxifen Citrate
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer
    NCT03367702
    Condition:   Stage II Prostate Adenocarcinoma
    Interventions:   Radiation: Intensity-Modulated Radiation Therapy (IMRT);   Radiation: Stereotactic Body Radiation Therapy (SBRT)
    Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
    Recruiting
  • ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab
    NCT01663402
    Condition:   Atherosclerotic Cardiovascular Disease
    Interventions:   Drug: Alirocumab;   Drug: Placebo;   Drug: LMT
    Sponsors:   Sanofi;   Regeneron Pharmaceuticals
    Completed
  • Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery
    NCT03180268
    Conditions:   Grade II Meningioma;   Intracranial Meningioma
    Interventions:   Other: Clinical Observation;   Radiation: Radiation Therapy
    Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
    Recruiting
  • Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
    NCT01547741
    Condition:   Breast Cancer
    Interventions:   Drug: Doxorubicin;   Drug: Cyclophosphamide;   Drug: Docetaxel;   Drug: Paclitaxel
    Sponsors:   NSABP Foundation Inc;   National Cancer Institute (NCI)
    Active, not recruiting
  • A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer
    NCT03009981
    Condition:   Prostate Cancer
    Interventions:   Drug: Apalutamide;   Drug: LHRH Analogue;   Drug: Abiraterone Acetate;   Drug: Prednisone
    Sponsors:   Alliance Foundation Trials, LLC.;   Janssen Research & Development, LLC
    Recruiting
  • Registrational Study With Omecamtiv Mecarbil/AMG 423 to Treat Chronic Heart Failure With Reduced Ejection Fraction
    NCT02929329
    Condition:   Heart Failure
    Interventions:   Drug: Omecamtiv Mecarbil;   Drug: Placebo
    Sponsors:   Amgen;   Cytokinetics;   Servier
    Active, not recruiting
  • FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer
    NCT02890355
    Conditions:   Metastatic Pancreatic Adenocarcinoma;   Recurrent Pancreatic Carcinoma;   Stage IV Pancreatic Cancer AJCC v6 and v7
    Interventions:   Drug: Fluorouracil;   Drug: Irinotecan Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Veliparib
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
    NCT02595905
    Conditions:   Breast Carcinoma Metastatic in the Brain;   Recurrent Breast Carcinoma;   Stage IV Breast Cancer AJCC v6 and v7;   Triple-Negative Breast Carcinoma
    Interventions:   Drug: Cisplatin;   Other: Laboratory Biomarker Analysis;   Other: Placebo Administration;   Drug: Veliparib
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • High-Dose Recombinant Interferon Alfa-2B, Ipilimumab, or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery
    NCT02506153
    Conditions:   Metastatic Cutaneous Melanoma;   Metastatic Non-Cutaneous Melanoma;   Non-Cutaneous Melanoma;   Recurrent Cutaneous Melanoma;   Recurrent Non-Cutaneous Melanoma;   Stage III Cutaneous Melanoma AJCC v7;   Stage III Mucosal Melanoma of the Head and Neck AJCC v7;   Stage IIIA Cutaneous Melanoma AJCC v7;   Stage IIIB Cutaneous Melanoma AJCC v7;   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7;   Stage IVA Mucosal Melanoma of the Head and Neck AJCC v7;   Stage IVB Mucosal Melanoma of the Head and Neck AJCC v7;   Stage IVC Mucosal Melanoma of the Head and Neck AJCC v7
    Interventions:   Biological: Ipilimumab;   Biological: Pembrolizumab;   Other: Quality-of-Life Assessment;   Biological: Recombinant Interferon Alfa-2b
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery
    NCT01150045
    Condition:   Colorectal Cancer
    Interventions:   Drug: celecoxib;   Drug: 5-fluorouracil;   Other: placebo;   Drug: oxaliplatin;   Drug: leucovorin
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
    Active, not recruiting
  • Platinum Based Chemotherapy or Capecitabine in Treating Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
    NCT02445391
    Conditions:   Estrogen Receptor Negative;   HER2/Neu Negative;   Invasive Breast Carcinoma;   Progesterone Receptor Negative;   Stage II Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage III Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Triple-Negative Breast Carcinoma
    Interventions:   Drug: Capecitabine;   Drug: Carboplatin;   Drug: Cisplatin;   Other: Laboratory Biomarker Analysis;   Procedure: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   ECOG-ACRIN Cancer Research Group;   National Cancer Institute (NCI)
    Recruiting
  • S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery
    NCT01120249
    Condition:   Kidney Cancer
    Interventions:   Drug: everolimus;   Other: placebo
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Active, not recruiting
  • S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer
    NCT02438722
    Conditions:   Recurrent Non-Small Cell Lung Carcinoma;   Stage IV Non-Small Cell Lung Cancer
    Interventions:   Drug: Afatinib Dimaleate;   Biological: Cetuximab;   Other: Laboratory Biomarker Analysis
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Active, not recruiting
  • Evaluation of Loratadine for Prevention of Pegfilgrastim-Induced Pain
    NCT01311336
    Condition:   Pegfilgrastim-induced Back and Leg Pain
    Interventions:   Drug: Loratadine;   Drug: placebo
    Sponsors:   University of Vermont;   Cancer and Leukemia Group B
    Unknown status
  • Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)
    NCT00310180
    Conditions:   Breast Adenocarcinoma;   Estrogen Receptor and/or Progesterone Receptor Positive;   Stage IA Breast Cancer AJCC v7;   Stage IB Breast Cancer AJCC v7;   Stage IIA Breast Cancer AJCC v6 and v7;   Stage IIB Breast Cancer AJCC v6 and v7;   Stage IIIB Breast Cancer AJCC v7
    Interventions:   Drug: Anastrozole;   Drug: Exemestane;   Other: Laboratory Biomarker Analysis;   Drug: Letrozole;   Other: Quality-of-Life Assessment;   Radiation: Radiation Therapy;   Drug: Tamoxifen Citrate
    Sponsors:   National Cancer Institute (NCI);   American College of Surgeons;   Cancer and Leukemia Group B;   NSABP Foundation Inc;   NCIC Clinical Trials Group;   North Central Cancer Treatment Group;   Southwest Oncology Group
    Active, not recruiting
  • Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
    NCT02152982
    Conditions:   Glioblastoma;   Gliosarcoma
    Interventions:   Other: Laboratory Biomarker Analysis;   Other: Placebo Administration;   Other: Quality-of-Life Assessment;   Drug: Temozolomide;   Drug: Veliparib
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery
    NCT00324805
    Conditions:   Stage IB Non-Small Cell Lung Carcinoma AJCC v7;   Stage IIA Non-Small Cell Lung Carcinoma AJCC v7;   Stage IIB Non-Small Cell Lung Carcinoma AJCC v7;   Stage IIIA Non-Small Cell Lung Cancer AJCC v7
    Interventions:   Biological: Bevacizumab;   Drug: Cisplatin;   Drug: Docetaxel;   Drug: Gemcitabine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Pemetrexed Disodium;   Other: Questionnaire Administration;   Drug: Vinorelbine Tartrate
    Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   NCIC Clinical Trials Group;   North Central Cancer Treatment Group;   Southwest Oncology Group
    Active, not recruiting
  • Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
    NCT00326898
    Conditions:   Clear Cell Renal Cell Carcinoma;   Stage I Renal Cell Cancer AJCC v6 and v7;   Stage II Renal Cell Cancer AJCC v7;   Stage III Renal Cell Cancer AJCC v7
    Interventions:   Other: Laboratory Biomarker Analysis;   Other: Placebo;   Other: Quality-of-Life Assessment;   Drug: Sorafenib Tosylate;   Drug: Sunitinib Malate
    Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   NCIC Clinical Trials Group;   Southwest Oncology Group
    Completed
  • Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
    NCT02048813
    Conditions:   Anemia;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacogenomic Study;   Other: Quality-of-Life Assessment;   Biological: Rituximab
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Relapsed Multiple Myeloma
    NCT02004275
    Condition:   Multiple Myeloma in Relapse
    Interventions:   Drug: pomalidomide;   Drug: ixazomib;   Drug: dexamethasone
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Celgene Corporation;   Millennium Pharmaceuticals, Inc.
    Recruiting
  • The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
    NCT01975389
    Condition:   Cardiovascular Disease
    Interventions:   Drug: bococizumab (PF-04950615);   Drug: Placebo
    Sponsor:   Pfizer
    Terminated
  • Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery
    NCT01953588
    Conditions:   Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Invasive Ductal Breast Carcinoma;   Invasive Lobular Breast Carcinoma;   Recurrent Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
    Interventions:   Drug: fulvestrant;   Drug: anastrozole
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
    Active, not recruiting
  • Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
    NCT01950390
    Conditions:   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7;   Unresectable Melanoma
    Interventions:   Biological: Bevacizumab;   Biological: Ipilimumab
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy
    NCT00769379
    Condition:   Ductal Breast Carcinoma In Situ
    Interventions:   Other: Laboratory Biomarker Analysis;   Biological: Trastuzumab;   Radiation: Whole Breast Irradiation
    Sponsors:   National Cancer Institute (NCI);   NRG Oncology
    Active, not recruiting
  • Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
    NCT01949337
    Conditions:   Adenocarcinoma of the Prostate;   Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
    Interventions:   Drug: enzalutamide;   Drug: abiraterone;   Drug: prednisone
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Astellas Pharma US, Inc.;   Medivation, Inc.;   Biologics, Inc.
    Active, not recruiting
  • S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
    NCT01903811
    Conditions:   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma
    Interventions:   Drug: Carfilzomib;   Drug: Dexamethasone;   Other: Laboratory Biomarker Analysis
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Active, not recruiting
  • Breast Cancer Registry for Participants With Breast Cancer or Characteristics of Hereditary Breast Cancer
    NCT00666731
    Conditions:   Breast Cancer;   Precancerous Condition
    Interventions:   Other: medical chart review;   Other: questionnaire administration;   Other: study of socioeconomic and demographic variables;   Procedure: Excess human biological tissue;   Procedure: quality-of-life assessment
    Sponsors:   University of Nebraska;   National Cancer Institute (NCI)
    Completed
  • A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome
    NCT00658515
    Condition:   Coronary Heart Disease
    Interventions:   Drug: Dalcetrapib (RO4607381);   Drug: Evidence-based medical care for Acute Coronary Syndrome;   Drug: Placebo
    Sponsor:   Hoffmann-La Roche
    Completed
  • Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
    NCT01764633
    Condition:   Dyslipidemia
    Interventions:   Biological: Evolocumab;   Drug: Placebo
    Sponsor:   Amgen
    Completed
  • Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events
    NCT01730534
    Conditions:   Diabetes Mellitus, Non-Insulin-Dependent;   High Risk for Cardiovascular Event
    Interventions:   Drug: Dapagliflozin 10 mg;   Drug: Placebo tablet
    Sponsors:   AstraZeneca;   Bristol-Myers Squibb;   The TIMI Study Group;   Hadassah Medical Organization
    Completed
  • Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer
    NCT01642251
    Conditions:   Extensive Stage Small Cell Lung Carcinoma;   Large Cell Lung Carcinoma;   Neuroendocrine Carcinoma;   Small Cell Carcinoma;   Stage IV Non-Small Cell Lung Cancer AJCC v7
    Interventions:   Drug: Cisplatin;   Drug: Etoposide;   Drug: Veliparib;   Drug: Placebo
    Sponsor:   National Cancer Institute (NCI)
    Completed
  • S1202: Duloxetine Hydrochloride for Muscle/Joint Pain in Early-Stage Breast Cancer Receiving Hormone Therapy
    NCT01598298
    Conditions:   Breast Cancer;   Musculoskeletal Complications;   Pain
    Interventions:   Drug: duloxetine hydrochloride;   Other: placebo
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Completed
  • Efficacy, Safety And Tolerability Study Of RN6G In Subjects With Geographic Atrophy Secondary to Age-related Macular Degeneration
    NCT01577381
    Condition:   Age-Related Maculopathy
    Interventions:   Biological: RN6G;   Biological: Placebo
    Sponsor:   Pfizer
    Terminated
  • Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
    NCT01575548
    Conditions:   Clear Cell Renal Cell Carcinoma;   Stage IV Renal Cell Cancer AJCC v7
    Interventions:   Drug: Pazopanib Hydrochloride;   Other: Pharmacological Study;   Other: Placebo Administration;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive and High-Risk, Lymph Node-Negative Breast Cancer
    NCT00433511
    Conditions:   Estrogen Receptor Negative;   Estrogen Receptor Positive;   HER2/Neu Negative;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
    Interventions:   Biological: Bevacizumab;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Paclitaxel;   Other: Placebo
    Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   ECOG-ACRIN Cancer Research Group;   North Central Cancer Treatment Group
    Active, not recruiting
  • Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
    NCT01225562
    Conditions:   Myocardial Infarction;   Cardiovascular Death;   Atherothrombosis;   Stroke
    Interventions:   Drug: Ticagrelor 90 mg;   Drug: Ticagrelor 60 mg;   Drug: Ticagrelor Placebo
    Sponsor:   AstraZeneca
    Completed
  • JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events
    NCT00239681
    Condition:   Elevated High-sensitivity C-Reactive Protein (hsCRP)
    Interventions:   Drug: Rosuvastatin;   Other: Placebo
    Sponsor:   AstraZeneca
    Terminated
  • Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
    NCT01169337
    Conditions:   Light Chain Deposition Disease;   Smoldering Plasma Cell Myeloma
    Interventions:   Other: Clinical Observation;   Drug: Lenalidomide;   Other: Quality-of-Life Assessment
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung
    NCT01154140
    Condition:   Non Squamous Lung Cancer
    Intervention:   Drug: treatment
    Sponsor:   Pfizer
    Completed
  • JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
    NCT01070836
    Condition:   Relapsing Multiple Sclerosis
    Intervention:   Drug: natalizumab
    Sponsor:   Biogen
    Completed
  • Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
    NCT00878709
    Condition:   Breast Cancer
    Interventions:   Drug: neratinib;   Other: placebo
    Sponsor:   Puma Biotechnology, Inc.
    Active, not recruiting
  • Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer
    NCT00785291
    Conditions:   Estrogen Receptor Negative;   Estrogen Receptor Positive;   HER2/Neu Negative;   HER2/Neu Positive;   Progesterone Receptor Negative;   Progesterone Receptor Positive;   Recurrent Breast Carcinoma;   Stage IIIC Breast Cancer AJCC v6;   Stage IV Breast Cancer AJCC v6 and v7
    Interventions:   Biological: Bevacizumab;   Drug: Ixabepilone;   Other: Laboratory Biomarker Analysis;   Drug: Nab-paclitaxel;   Drug: Paclitaxel;   Other: Questionnaire Administration
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • Evaluation of Efficacy and Safety of Lovaza (Omega-3-Acid Ethyl Esters) in Recurrent, Symptomatic Atrial Fibrillation
    NCT00402363
    Condition:   Fibrillation, Atrial
    Interventions:   Drug: omega-3-acid ethyl esters;   Drug: Placebo
    Sponsor:   GlaxoSmithKline
    Completed
  • Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
    NCT00382070
    Condition:   Breast Cancer
    Interventions:   Drug: Letrozole;   Other: Placebo
    Sponsors:   NSABP Foundation Inc;   National Cancer Institute (NCI);   Novartis
    Active, not recruiting
  • Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas
    NCT03984448
    Conditions:   Diffuse Large B-Cell Lymphoma;   Double-Expressor Lymphoma;   High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements;   High Grade B-Cell Lymphoma, Not Otherwise Specified;   Neoplastic Cells With Double Expression of MYC and BCL2 Proteins Present
    Interventions:   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Prednisone;   Biological: Rituximab;   Drug: Venetoclax;   Drug: Vincristine;   Drug: Vincristine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Prevalence of PD-L1 Expression in Patients With Advanced Urothelial Carcinoma
    NCT03788746
    Condition:   Urothelial Carcinoma
    Intervention:  
    Sponsor:   AstraZeneca
    Recruiting
  • TMC114-C226: An Early Access Program to Evaluate the Long-term Safety and Tolerability of TMC114 Combined With a Low Dose of Ritonavir (TMC114/r) With Other Antiretrovirals, for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens.
    NCT00245739
    Condition:   HIV Infections
    Intervention:   Drug: TMC-114
    Sponsor:   Tibotec Pharmaceuticals, Ireland
    Approved for marketing
  • Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
    NCT03678025
    Conditions:   Castration Levels of Testosterone;   Metastatic Prostatic Adenocarcinoma;   Stage IV Prostate Cancer AJCC v8;   Stage IVA Prostate Cancer AJCC v8;   Stage IVB Prostate Cancer AJCC v8
    Interventions:   Drug: Abiraterone;   Drug: Bicalutamide;   Drug: Degarelix;   Drug: Docetaxel;   Drug: Flutamide;   Drug: Goserelin Acetate;   Drug: Histrelin Acetate;   Drug: Leuprolide Acetate;   Drug: Nilutamide;   Procedure: Orchiectomy;   Drug: Prednisone;   Other: Quality-of-Life Assessment;   Radiation: Radiation Therapy;   Procedure: Radical Prostatectomy;   Drug: Triptorelin
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting

Popular Now

  • Privacy Policy
  • Ad and Cookie Policy
  • Infringement Policy
  • Terms of Use
  • Email Policy
  • Contact Us
  • Post Clinical Trials
  • Join Clinical Trials
  • Volunteer Login
  • Recruiters Login
  • Frequently Asked Questions
  • Blog
  • Find Clinical Trials
  • Find Volunteers
  • Trials by Category
  • Trials by Location
  • Volunteers by Category
  • Volunteers by Location
All clinical trials are registered and certified with clinicaltrials.gov. Data via U.S. National Library of Medicine,U.S. National Institutes of Health, U.S. Department of Health & Human Services. JoinClinicaltrials.com (Aunica Media llc) is a free resource that provides individuals and companies with information regarding clinical trials that are being conducted nationwide. Aunica Media llc does not conduct clinical trials nor endorses them. Please consult your doctor or physician before participating. And Ye shall know the truth, and the truth shall make you free
©2001-2019 Aunica Media LLC